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Abstract
Background: The etiologic heterogeneity of cancer has traditionally been investigated by comparing risk factor
frequencies within candidate sub-types, defined for example by histology or by distinct tumor markers of interest.
Increasingly tumors are being profiled for molecular features much more extensively. This greatly expands the
opportunities for defining distinct sub-types. In this article we describe an exploratory analysis of the etiologic
heterogeneity of clear cell kidney cancer. Data are available on the primary known risk factors for kidney cancer, while
the tumors are characterized on a genome-wide basis using expression, methylation, copy number and mutational
profiles.
Methods: We use a novel clustering strategy to identify sub-types. This is accomplished independently for the expression,
methylation and copy number profiles. The goals are to identify tumor sub-types that are etiologically distinct, to identify
the risk factors that define specific sub-types, and to endeavor to characterize the key genes that appear to represent the
principal features of the distinct sub-types.
Results: The analysis reveals strong evidence that gender represents an important factor that distinguishes disease
sub-types. The sub-types defined using expression data and methylation data demonstrate considerable congruence and
are also clearly correlated with mutations in important cancer genes. These sub-types are also strongly correlated with
survival. The complexity of the data presents many analytical challenges including, prominently, the risk of false discovery.
Conclusions: Genomic profiling of tumors offers the opportunity to identify etiologically distinct sub-types, paving the
way for a more refined understanding of cancer etiology.
Keywords: Etiologic heterogeneity, Kidney cancer, Tumor sub-types
Background
In the past several years much effort has been expended
in identifying tumor sub-types that are clinically distinct,
using genome-wide molecular profiling [1]. Most of the
attention has been directed at expression arrays, but
other profiling tools have also been studied. Investigators
have typically “validated” the discoveries by demonstrat-
ing that the sub-types possess distinct clinical character-
istics, such as case survival. Relatively little attention has
been paid to the goal of distinguishing sub-types on the
basis of etiology. Etiologic heterogeneity of cancer has
traditionally been investigated by comparing risk factor fre-
quencies within candidate sub-types, defined for example
by histology or by distinct tumor markers of interest. In
kidney cancer several studies have explored the relation of
tumors with mutations in the von-Hippel-Lindau (VHL)
gene to risk factors such as history of smoking and hyper-
tension [2-4]. More general reviews of research relating
risk factors to epigenomic profiles have been compiled re-
cently, though the statistical methodology for establishing
etiologically distinct sub-types based on genomic profiles
in the presence of multiple risk factors is largely undevel-
o p e d[ 5 , 6 ] .S i n c em o r ee x t e n s i v eg e n o m i cp r o f i l i n go ft u -
mors is likely to become commonplace in the future
epidemiologists will be focusing increasing attention on
the task of discovering etiologically distinct sub-types,
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specific candidate markers. This exercise will be challen-
ging due to the vast amounts of genomic data available on
modern tumor profiling platforms and the consequent
risks of false discovery.
In this article we present a prototype discovery analysis
using data from The Cancer Genome Atlas (TCGA). We
have available several hundred cases from the (clear cell)
kidney TCGA for which data have also been assembled on
the known risk factors for kidney cancer. We build on an
analytic strategy that was developed by members of our
team and used previously to study the etiologic heterogen-
eity of breast cancer [7]. The breast cancer analysis in-
volved data from two large case-control studies [8,9].
However, the tumors were characterized by only 4 expres-
sion markers, and so the capacity to define sub-types was
extremely limited. Our present dataset contrasts with this
in that the tumors have all been extensively profiled using
multiple genomic platforms. Also, our sample is restricted
to cases. Thus the present study is extremely rich in tumor
profiling, allowing us to evaluate much more completely
and rigorously our proposed techniques for identifying
etiologically distinct sub-types.
The goals of the article are two-fold. First, we en-
deavor to demonstrate a novel strategy for identifying
etiologically distinct tumor sub-types from extensive
tumor profiling data, and to explore the methodo-
logical challenges. Second we seek to discover clues
about the distinctive etiologies of different types of
kidney cancer.
Methods
We use publically available genomic profiling data gen-
erated by the TCGA, together with data on known risk
factors for kidney cancer extracted from medical re-
cords. The study was approved by the Memorial Sloan
Kettering Cancer Center Institutional Review Board/
Privacy Board, the University of Pittsburgh Institutional
Review Board, the Biomedical IRB of the University of
North Carolina, the Dana Farber Cancer Institute Of-
fice for Human Research Studies and the MD Anderson
Cancer Center Institutional Review Board. The data
were obtained from chart review from the source sites
of the TCGA in accordance with the individual sites’
IRBs. All patients provided written informed consent
for the use of their records. Each participating institu-
tion updated the clinical information for its own pa-
tients. Some of the authors on the study are clinicians
that treated the patients within the TCGA and thus had
access to specific patient records. Initial analyses of the
kidney TCGA revealed four sub-types identified by
clustering the mRNA data that were observed to be
characterized by distinctive mutational profiles [10].
Data
Cases were selected for the TCGA project based on pa-
tient consent and the availability of adequate tissue for
the intensive planned mutational analyses. Thus the se-
lection of cases cannot be considered representative of
all diagnosed cases and may result in a preponderance of
features characteristic of more advanced cases with lar-
ger tumors or may under-represent metastatic cases that
frequently do not undergo nephrectomy.
We elected to focus on four distinct genomic plat-
forms: mRNA, copy number, methylation and mutation.
mRNA expression results were generated from the Illu-
mina HiSeq platform. We used normalized log counts
and filtered out genes with low expression (median <5
counts) and low variability (MAD <1.25), following
standard practice of TCGA investigations leaving 1267
genes from the original panel of 20531. Methylation data
were generated from the Illumina 27k and 450k panels
as described previously [8]. A total of 25014 probes were
examined, with the sex chromosome excluded. Data
were standardized across samples and within platform
and merged, and the top 1000 most variable probes se-
lected for analysis. Copy number data were derived from
Affymetrix SNP 6.0 arrays. We used a reduction param-
eter (ε=0.001) to obtain a total of 2312 regions, and our
data comprise the segment means from each region.
These filtering approaches are based on the premise that
about 1000 probes is sufficient to capture any relevant
structure in the data, while the addition of more probes,
especially those with low signal or low variance, is likely
to add noise. Mutation data were obtained from the sup-
plementary files of the original publication of the TCGA
without any additional processing [10].
Risk factor data were obtained from the medical records.
We obtained information on smoking status at diagnosis
(current, former, never smoker), body mass index (BMI)
categorized in accordance with World Health Organization
criteria (<25, 25-29, 30+ kg/m
2)a n dl i f e t i m eh i s t o r yo f
hypertension (yes, no), all of which are established risk
factors for kidney cancer [11-14]. In addition we include
age and gender, since cancer incidence in general is influ-
enced by both of these factors. Instructions for how to
reconstruct the data are provided in Additional file 1
Supplementary Materials (Data Archive).
Analytic framework
Details of our general analytic strategy were explained
in a previous article [7]. In the following we summarize
the essential conceptual features of the approach, and
some modifications we have made to suit the nature of
the TGCA data, namely the extensiveness of the gen-
omic profiling and the fact that the study is limited to
cases with cancer but not healthy controls. Our primary
goal is to identify tumor sub-types that are etiologically
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strategy that employs classical k-means clustering using
the genomic profiles of the tumors to identify candidate
solutions. K-means clustering endeavors to find the set
of clusters that maximizes the weighted Euclidean dis-
tance between the clusters using the inter-cluster dis-
similarity, denoted by G, as the distance measure.
Because of the complexity of identifying the maximum
of a scalar function in multi-dimensional space k-means
clustering from an initial random seed inevitably
reaches a local maximum rather than the global
maximum. Thus the method involves repeated
maximization using different random seeds, with the
maximum of the various local maxima chosen as the
ultimate solution. In our approach, rather than choos-
ing the solution with the highest value of G, for each
local maximum we calculate a measure of etiologic
heterogeneity and choose the solution with the highest
value of this measure. We used 10,000 k-means runs
for this purpose. Empirically the individual values of
the clustering measure identified (defined below) were
each observed sufficiently frequently that we are
confident we did not fail to identify the maximum.
Each clustering analysis involves initial specification of
the number of clusters. That is, we perform an analysis
based on the assumption that there exist 2 clusters,
then we perform an analysis based on 3 clusters, and
so forth.
Our measure of etiologic heterogeneity is based on
two related concepts. The first is that in studying risk
factors we desire to maximize the predictability of dis-
ease occurrence in individuals, and that a useful measure
of predictability is the extent of variation of the risks of
individuals in the population. That is, the more widely
varying the individual risks, the more easily we are able
to predict the disease. We use for this purpose the coef-
ficient of variation of disease risks, denoted by K, a
measure that aggregates the relative contributions of
individual risk factors. In any disease sub-type the cor-
responding coefficient of variation of the risks of the
sub-type is denoted Kj for sub-type j. That is, if ri is
the overall disease risk for the i
th individual and rji is
the corresponding risk of sub-type j, then Κ=v
1/2/ʼ
and Κj ¼ v
1=2
j =ʼj; where ʼ ¼ n−1X
ri; v ¼ n−1X
r2
i −ʼ2;
ʼj ¼ n−1X
rji;vj ¼ n−1X
r2
ji−ʼ2
j ; and where n is the num-
ber of subjects in the population at risk. The etiologic het-
erogeneity of sub-types can be characterized by the
correlations of the risks of the individual sub-types, with
low (or negative) correlation representing high degrees of
heterogeneity. Thus the coefficients of covariation, Κjk=
cjk/ʼjʼk,w h e r ecjk=n
−1∑rjirki−ʼjʼk, reflect (inversely) the
degrees of etiologic heterogeneity between pairs of sub-
types. The second concept is that increasing etiologic het-
erogeneity between sub-types inevitably increases the col-
lective risk predictability within sub-types. Thus by using
a measure of incremental risk prediction denoted by
D ¼ ˀ1Κ2
1 þ ˀ2Κ2
2 þ :::: þ ˀΚ2
m
  
−Κ2 ð1Þ
where ˀ1,ˀ2, …ˀm represent the proportions of cases in
each of m sub-types, we are able to choose sets of sub-
types that maximize the extent to which the average risk
predictability of the set of sub-types (the term in paren-
theses) exceeds the risk predictability of the disease as a
unitary entity (as represented by K
2), and by so doing we
also maximize the collective etiologic heterogeneity of
the sub-types. This can be seen by observing that D can
also be written in the following way, showing that it in-
creases with decreasing values of the covariances:-
D ¼ ˀ1ˀ2 Κ2
1 þ Κ2
2−2Κ12
  
þ ˀ1ˀ3 Κ2
1 þ Κ2
3−2Κ13
  
þ ::::: ð2Þ
where the summation extends to all pairs of sub-types.
To calculate the various coefficients of variation and
covariation one needs to obtain risk predictors for each
sub-type for each case. In the context of a case-control
study these can be obtained from polytomous logistic re-
gression of the sub-types on the risk factors, as described
in our previous work [7]. However, the kidney TCGA
dataset contains only cases, with no disease-free con-
trols. The case-only design permits estimation of the ra-
tios of the relative risks of the different sub-types for any
subject but does not permit estimation of the relative
risk of disease itself [15]. However, we can calculate an
approximation to D, denoted D
*, that captures the essen-
tial features of the heterogeneity signal as follows.
The preceding formulas (1) and (2) represent averages
with respect to the population at risk. Since the controls
in a case-control study represent the population at risk
the variance and covariance components of the formulas
must be estimated by averaging over the controls. In a
case-only study we can only calculate such terms using
cases, and so corresponding summation terms represent
averages over the population distribution of cases. Cases
occur based on risk-biased sampling from the popula-
tion at risk, and so the various terms we use in calculat-
ing our measure of etiologic heterogeneity are averaged
with respect to this risk biased sample. Risk biased sam-
pling means that individuals become cases in direct
proportion to the individual’s risk. Consequently to decon-
volute the distribution of risks obtained from a sample of
cases in order to equate it with the corresponding distri-
bution from controls one would have to reweight each
case in inverse proportion to its risk, i.e. the i
th case must
be reweighted by the factor ʼ/ri, relative risks that are not
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sence of controls we must simply estimate the variance
and covariance terms that comprise D using the cases. To
see the impact of this we make use of the fact that D can
be re-expressed in terms of individual, case-specific devia-
tions of the sub-type probabilities from their overall rela-
tive frequencies as follows:-
D ¼ n−1 X
j;k;j<k
ˀjˀk
X
i
ri
ʼ
   2 uji
ˀj
−
uki
ˀk
   2
; ð3Þ
where uji=rji/ri represents the conditional probability that
the i
th case belongs to the j
th sub-type. The last term in
parentheses represents the deviation of the sub-type prob-
abilities for the i
th case for the j
th and k
th sub-types.
Greater etiologic heterogeneity is reflected by larger values
of these deviations. If we simply use cases to estimate the
variances and covariances that comprise D in (1)t h e nw e
are in effect estimating D
*,w h e r e
D  ¼ n−1 X
j;k;j<k
ˀjˀk
X
i
ri
ʼ
  
ri
ʼ
   2 uji
ˀj
−
uki
ˀk
   2
ð4Þ
That is, the contributions of individual cases are add-
itionally weighted in proportion to their risks via the
terms {ri/ʼ}. The effect of this change will be to give
greater weight in (4) to risk strata with higher risks and
correspondingly lesser weight to risk strata with lower
risk. We cannot compare these terms empirically since
we have no controls, but it is clear that the impact of
the difference will be minimal unless there is both a very
broad range of individual risks, and a trend for the “out-
liers” to occur preferentially at one end of the risk scale.
Moreover, the goal of our analysis is not to evaluate the
absolute magnitude of D. It is to use relative values of D
to rank different sub-typing options to determine which
ones exhibit the greatest degrees of etiologic heterogen-
eity. Intuitively the rankings of D and D* are likely to be
very similar in practice, even in the presence of broad
variation in the underlying risks.
We evaluated the statistical significance of the hypothesis
that heterogeneity exists in the data in the following way.
We determined the value of D* from the optimal 2-class
system and compared this with a reference distribution in
which the sample labels were permuted 1000 times and D*
recalculated for the new dataset. Permutation of the sample
labels ensures that the genomic profiles are randomly paired
with the risk factor profiles, defining the absence of a true
signal. Determination of the correct number of sub-types is
a challenge in any clustering context but it is especially
challenging in this context. He r ew ec h o s et ou s et h ed i f f e r -
ence in the optimal D* values for the numbers of sub-types
being compared, e.g. in determining whether 3 sub-types re-
veals significant additional heterogeneity to 2 sub-types we
subtracted the optimal D* for the 2-class analysis from the
optimal value for the 3-class analysis. We generated a ref-
erence distribution by permuting the sample labels, calcu-
lating the optimal 3-class and 2-class solutions, calculating
the difference, and repeating the process 1000 times.
Our investigation is exploratory. Since genomic data are
so voluminous and we have results from multiple plat-
forms we approached the analysis with some specific
questions in mind, to provide structure to our analysis and
to enhance our confidence in any interesting observations.
First we performed the preceding clustering analysis sep-
arately for each of 3 platforms: mRNA, methylation and
copy number arrays. Then we attempted to address the
following questions:- Do any of the identified sub-types
possess a distinctive risk profile? Are any sub-types deter-
mined from mRNA, methylation or copy number data
characterized by distinct mutational profiles or genetic
pathways? Do the individual sub-types have distinctive
clinical characteristics? Are the different genomic plat-
forms congruent with respect to sub-types identified?
To address the involvement of genetic pathways a gene
set enrichment analysis was conducted. We obtained a
pre-defined collection of pathway gene sets from the
Molecular Signatures Database (MSigDB database v4.0)
and the database for Annotation, Visualization, and Inte-
grated Discovery (DAVID). We conducted a gene set en-
richment analysis for each of the subtypes for each of
the platforms. Specifically, for each platform we first cal-
culated a t-statistic for each gene j comparing samples in
sub-type k (k =1,..,4) versus the remaining sub-types.
Genes were ranked based on these scores. Then for each
gene set S, a Wilcoxon rank sum test was used to com-
pare the ranks of genes in the pathway (j ∈ S) versus
their complement (j ∉ S). In this way we calculated a
separate enrichment p-value for each pathway in each of
the four subtypes. This can be considered a competitive
test in the nomenclature of Goeman and Buelmann in
that the Wilcoxon test statistic assesses whether the fre-
quency of differential expression differs for pathway
genes versus non-pathway genes [16].
Results
The TCGA dataset comprises 442 cases of clear cell renal
cancer. Data on risk factors were retrieved from medical re-
cords at Memorial Sloan Kettering Cancer Center, the Uni-
versity of North Carolina, the University of Pennsylvania
Medical Center, Dana-Farber Cancer Institute, and MD
Anderson Cancer Center for a total of 332 of these cases,
and these form the basis for our analyses.
Distinctiveness of sub-types identified with respect to risk
profiles
We conducted analyses for each of the genomic plat-
forms separately. We tested first for the presence of
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tion profiling exhibiting statistically significant hetero-
geneity (p<0.01) while copy number profiling did not
(p=0.11). It has been observed that copy number alter-
ations occur much less frequently in this disease than in
other cancers examined in the TCGA project [10]. We
then explored the optimal numbers of potential sub-
types for mRNA and methylation profiling. The results
of our tests are displayed in Table 1. These do not dem-
onstrate a consistent pattern, suggesting around 3-4 sub-
types based on mRNA profiling but a larger number of
sub-types based on methylation profiling. In the absence
of consistency we have elected to present results only
for the 4-class solutions. This facilitates comparison of
the solutions in different platforms and also with the 4
class solution derived by the TCGA investigators using
unsupervised clustering [10].
Consider first the analysis involving mRNA expression
data. This analysis is based on 313 cases. We performed
the clustering 10,000 times using different random seeds
and this led to 533 unique solutions at local maxima.
The D
* measure of etiologic heterogeneity (Y-axis) and
the corresponding distance measure G (X-axis) are plot-
ted in Figure 1 in red for each of these 533 solutions.
The black dots represent solutions in which the cases
are randomly assigned to 4 sub-types to create datasets
in which the sub-types are not associated with the tumor
profiles. Thus these black dots benchmark the G values
expected when there is no genuine sub-structure to the
gene expression profiles. If the gene expression sub-
structure is associated with the risk factors then we
would expect the D
* values corresponding to the red
dots to be stochastically larger than those of the black
dots as seen in the figure. The “optimal” solution is the
highest of the red dots on the vertical axis. By contrast,
a standard unsupervised clustering solution would be
based on the largest value of G (horizontal axis). Clearly
these two solutions are quite far apart in Figure 1, and
indeed they represent sets of sub-types with only modest
overlap. A cross tabulation of the 4 classes created by
these two solutions shows that at most we can align 49%
of the cases into congruent classes; the remaining 51%
are necessarily incongruent.
In Table 2 we present the distributions of risk factors
within each of the sub-types. Since between-class distinc-
tions in these profiles drive the creation of the sub-types
we cannot use conventional statistical tests to assess the
statistical significance of observed differences. The results
seem to show that sub-type 4 has a strong female predom-
inance relative to the other sub-types, and this sub-type is
also characterized somewhat by low prevalence of smok-
ing and elevated history of hypertension.
We performed an analogous clustering analysis using
methylation data. Data were available on 326 cases. We
again performed the clustering 10,000 times using differ-
ent random seeds and this led to 114 unique solutions at
local maxima. The distributions of risk factors for the sub-
types in the “optimal” solution are displayed in Table 3.
The most striking observation is that sub-type 4 has ele-
vated representation of both females and cases with a his-
tory of hypertension, similar to the results for mRNA.
Again, no apparent differences strongly distinguish the
remaining 3 classes. These sub-types have been arbitrarily
numbered to identify most closely congruences with the
clusters derived using mRNA data, using the 313 cases for
which results are available for both mRNA and methyla-
tion. Thus sub-type 1 mRNA has the most overlap with
sub-type 1 methylation, and so forth.
Mutational profiles of sub-types
We observed some quite strong associations between
the mRNA and methylation sub-types and mutations in
selected genes. The data are displayed in Tables 4 and 5,
respectively. The most notably distinct mRNA sub-types
are sub-type 3, characterized by BAP1, PTEN and TP53
mutations, and sub-type 4, characterized by elevated fre-
quencies of VHL and PBRM1 mutations. Strikingly, the
methylation classification sub-type 4 also exhibits high
frequency of PBRM1 mutations while sub-type 1 ex-
hibits low frequencies. Similar congruence was seen for
methylation sub-type 3 which is also characterized by
BAP1 and TP53 mutations, although elevated frequency
of PTEN mutations was not observed.
Gene set enrichment analysis revealed that the solute
carriers (SLC) transporter gene family was the pathway
most differentially expressed in mRNA sub-type 4 (al-
though it did not exceed the Bonferroni correction for
multiple testing). Many SLCs are involved in metabolism
and kidney cancer has been characterized as a metabolic
disease [17]. Changes in transporter expression can affect
the movement of drugs and their metabolites across cell
membranes and thus impact drug sensitivity [18]. SLC-
transporter expression has been associated with chemo-
sensitivity in various cancer types including kidney cancer
[19,20]. Such an expression difference observed for the
SLC gene family may be potentially important to explain
Table 1 Selecting the optimal number of clusters
Incremental
# sub-types
P-values
a
mRNA Methylation
3v s2 0.02 <0.01
4v s3 0.06 0.04
5v s4 0.41 <0.01
aThe p-values determine whether the designated increase in the numbers of
clusters leads to significant additional etiological heterogeneity, as described
in the text.
Begg et al. BMC Medical Research Methodology 2014, 14:138 Page 5 of 10
http://www.biomedcentral.com/1471-2288/14/138differences in tumor biology and may have treatment im-
plications for this female-predominant expression sub-
type. The most significant pathway affecting methylation
sub-type 4 was transcription regulation, suggesting that ex-
pression changes associated with this subtype may be
methylation-driven. Indeed, several SLC family genes in-
cluding SLC16A5 and SLC13A1 show negative association
between methylation and gene expression.
Clinical characteristics of sub-types
Conventional methods for determining tumor sub-types,
as employed by the TCGA investigators and many other
groups, involve the use of unsupervised clustering, and
validation of the biologic significance of the sub-types is in
part determined by whether the sub-types display distinct
clinical characteristics such as distinctive distribution of
histology, stage or survival. The TCGA sub-types obtained
using unsupervised clustering demonstrate quite substan-
tial and highly significant differences in survival [10]. The
c-index associated with the TCGA mRNA sub-types is
0.63. However, the mRNA sub-types determined on the
basis of etiologic heterogeneity also demonstrate strong
and highly significant survival differences with a similar
c-index of 0.62 (Figure 2). Likewise the methylation sub-
types display strong and significant separation on the basis
of survival with a c-index of 0.63 (Figure 3). In short, our
method succeeded in obtaining sub-types optimally clus-
tered on the basis of etiologic heterogeneity without appar-
ently sacrificing any association with survival. Note that
these comparisons are appropriately unadjusted for prog-
nostic factors such as stage since the goal is to see if the
sub-types are clinically distinctive in an absolute sense.
Congruence of sub-types across platforms
Ideally the analyses using different platforms would suggest
similar sub-types, giving us confidence that the clustering
is producing verifiable sub-types. The numbers of cases
that are congruent for mRNA and methylation sub-types
1, 2, 3 and 4 are, respectively, 26, 39, 39 and 48, leading to
an overall congruence of 152 (49%) of the cases, versus 79
(25%) expected if the categories were generated randomly
(p <0.001). Of these the most credible overlap of sub-types
with similar risk factor profiles is between sub-type #4 for
both mRNA and methylation. Both of these sub-types have
a strong female predominance, and also the suggestion of a
Figure 1 Distributions of clustering solutions. The red dots represent local maxima of unsupervised clustering based on G (horizontal axis).
The black dots represent solutions based on random permutations of case labels for which no signal on either axis is present.
Table 2 Expression sub-types
a
Risk factor Sub-
type 1
Sub-
type 2
Sub-
type 3
Sub-
type 4
n= 74 n= 83 n=71 n=85
Smoking Never 45% 40% 47% 66%
Former 41% 36% 47% 25%
Current 15% 24% 7% 9%
BMI Normal 23% 22% 24% 17%
Overweight 35% 28% 44% 28%
Obese 42% 51% 32% 55%
Hypertension No 38% 52% 45% 33%
Yes 62% 48% 55% 67%
Gender Male 70% 78% 72% 41%
Female 30% 22% 28% 59%
Age Median 62 58 61 63
aThe entries represent the relative frequencies of the risk factors within sub-types.
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platforms is characterized by BAP1 and TP53 mutations.
Discussion
Previous investigations of the molecular epidemiology of
kidney cancer have focused attention on cases classified
on the basis of mutations in the VHL gene which has been
recognized for many years as a source of common early
mutations in the development of this disease [21,22]. A
study by van Dijk et al. [2] concluded that smoking is un-
related to VHL mutations but a later study by Moore et al.
[4] appears to contradict this finding. Schouten et al. [3]
provide evidence that hypertension is positively associated
with the occurrence of VHL mutant cases while diur-
etic use is associated with VHL negative tumors.
However, in all of these studies the associations ob-
served are modest. Our approach has been to address
the molecular epidemiological associations in an ex-
ploratory fashion using a much larger compilation of
genetic markers.
We have presented a prototype investigation of this
strategy, making use of the availability of risk factor data
on a series of cases that have been extensively profiled as
part of the TCGA project. We anticipate that data on ex-
tensive tumor profiling will become increasingly available
in case-control and other epidemiologic investigations,
and so we have outlined some options for approaching the
analysis of these kinds of study. Because of the vast quan-
tities of genomic data the analysis is inevitably built
around the concept of clustering, a statistical strategy de-
signed to identify groups of cases that are “similar”,a n d
thus may represent distinct disease sub-types. A major
concern in all clustering analyses is the strong possibility
of false discovery, and this is certainly a possibility in our
study. To convince ourselves that sub-types identified
from clustering techniques are meaningful, the ideal valid-
ation would be a repeat study in which similar clusters
emerge. In the absence of a replicate study we judge the
believability of our results using somewhat heuristic strat-
egies. One of these is to examine whether the sub-types
are clinically distinctive. On this basis our survival analyses
are reassuring, in that they demonstrate strong and statisti-
cally significant differences between the sub-types. Another
approach we have examined is to see if sub-types deter-
mined by different genomic platforms are congruent. There
is some evidence that two of the classes identified inde-
pendently by mRNA and methylation profiling demonstrate
considerable concordance, but the evidence here appears
suggestive rather than conclusive. We also examined the
Table 3 Methylation sub-types
a
Risk factor Sub-
type 1
Sub-
type 2
Sub-
type 3
Sub-
type 4
n= 80 n= 83 n=70 n=93
Smoking Never 49% 58% 40% 48%
Former 44% 23% 46% 37%
Current 8% 19% 14% 15%
BMI Normal 13% 22% 30% 22%
Overweight 41% 25% 33% 34%
Obese 46% 53% 37% 44%
Hypertension No 53% 46% 46% 25%
Yes 47% 54% 54% 75%
Gender Male 75% 63% 71% 53%
Female 25% 37% 29% 47%
Age Median 62 54 61 64
aThe entries represent the relative frequencies of the risk factors within sub-types.
Table 4 Mutations in mRNA sub-types
a
Gene #
Cases
Sub-type
1
Sub-type
2
Sub-type
3
Sub-type
4
p-
value
n=74 n=83 n=71 n=85
VHL 162 58% 54% 39% 69% .003
PBRM1 97 32% 39% 12% 46% <.001
SETD2 36 10% 14% 12% 12% .90
BAP1 33 13% 6% 24% 5% .001
MTOR 22 6% 9% 7% 9% .90
ADAM6 22 4% 6% 4% 14% .07
MST1P2 22 6% 10% 6% 8% .76
PDE4DIP 18 7% 3% 6% 9% .48
KDM5C 17 10% 6% 4% 3% .24
PTEN 12 6% 1% 10% 0% .009
TP53 8 1% 1% 9% 0% .006
aThe entries represent the frequencies of occurrence of mutations in the
given genes.
Table 5 Mutations in methylation sub-types
a
Gene #
Cases
Sub-type
1
Sub-type
2
Sub-type
3
Sub-type
4
p-
value
n=80 n=83 n=70 n=93
VHL 162 48% 61% 45% 64% .04
PBRM1 97 12% 31% 31% 55% <.001
SETD2 36 5% 6% 23% 15% .003
BAP1 33 11% 4% 25% 7% <.001
MTOR 22 8% 6% 6% 10% .80
ADAM6 22 5% 7% 5% 12% .30
MST1P2 22 9% 10% 8% 4% .41
PDE4DIP 18 7% 6% 6% 6% 1.00
KDM5C 17 7% 3% 5% 8% .50
PTEN 12 8% 0% 5% 4% .11
TP53 8 4 %0 %8 %1 % . 0 4
aThe entries represent the frequencies of occurrence of mutations in the
given genes.
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and methylation profiling, and here the evidence is stron-
ger, with mutation frequencies in some genes strongly and
significantly associated with individual sub-types. Collect-
ively, these facts give us some confidence that the sub-types
identified represent real classes with distinctive biological
and clinical characteristics.
Our major finding that appears supported by strong evi-
dence is the identification of a sub-type that has an ele-
vated female representation compared to other sub-types.
This is a clear and striking result that emerges independ-
ently from both the mRNA and the methylation profiling.
The importance of gender in this disease has been
suggested by others, since gender is known to affect both
incidence and survival [23]. Recently Brannon et al. have
integrated data from multiple genomic studies and have
observed that one of the major sub-types clearly segre-
gates along gender lines [24]. Additionally, this sub-type
seems to be characterized by mutations in the PBRM1
gene which is located close to the VHL gene in the 3p re-
gion [25]. Another sub-type that emerges from both
mRNA and methylation profiling appears to be character-
ized by mutations in BAP1 and TP53.
Our study has limitations. The sample size was limited
by the numbers collected for the TCGA project and as
such is modest for the ambitious goals of identifying
what may actually be many sub-types. Much larger sample
sizes are necessary to confidently identify sub-types, espe-
cially sub-types with lower frequencies of occurrence. As
in all analyses of voluminous genomic data many arbitrary
decisions need to be made prior to conducting the ana-
lyses. These include, for example, pre-processing decisions
that affect the number of probes included in the analysis,
the arbitrary exclusion of solutions that contain sub-types
with very low numbers of cases, and others. These arbi-
trary decisions could affect the conclusions. Risk factor
data were abstracted from medical records. Smoking status
is based on self-report, pre-surgical BMI may be impacted
by disease-related weight loss, and history of hypertension
does not reflect duration or management of the disease.
Hormonal and reproductive factors for women were not
available. The absence of controls requires us to use a
slightly modified version of the measure of heterogeneity
that we proposed in previous work in the context of case-
control data. It has been shown that in a case-control set-
ting essentially all of the relevant information concerning
etiologic heterogeneity is contained in the “case” informa-
tion, since it is contrasts in the risk profiles of cases that
characterize etiologic heterogeneity [26]. Consequently the
use of our modified measure should have minimal, if any,
impact on the results that would have been obtained if
controls had been available. Finally determination of the
correct number of sub-types is challenging. Our statistical
test for determining if the addition of an extra sub-type sig-
nificantly increases the observed heterogeneity signal used
a reference distribution in which the differences in the op-
timal values of D* for the competing numbers of clusters
were calculated repeatedly from datasets in which the sub-
ject labels were permuted. We constructed the test this
way because it is not evident how to assess the null incre-
ment in D* beyond the optimal D* observed for the lower
number of sub-types. Further research is needed to clarify
the operating characteristics of our approach and possibly
refine it. More importantly, there is a true underlying set of
sub-types, and the fact that the different platforms were not
congruent with respect to the numbers of sub-types identi-
fied by our testing algorithm demonstrates considerable
Figure 2 Survival of mRNA sub-types. Kaplan-Meier survival
curves for cases classified in 4 mRNA sub-types.
Figure 3 Survival of methylation sub-types. Kaplan-Meier survival
curves for cases classified in 4 methylation sub-types.
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http://www.biomedcentral.com/1471-2288/14/138uncertainty in the data regard i n gt h et r u en u m b e ro fs u b -
types.
Conclusions
Our study is a demonstration of a novel analysis of etio-
logic heterogeneity taking advantage of the abundant
genomic resources available from the TCGA project.
Due to a limited sample size the results are necessarily
speculative. Our primary observation is that there exists
a distinctive sub-type characterized by female gender,
and also by PBRM1 mutations. We also observed that
the sub-types identified by mRNA and methylation pro-
filing have significantly distinct survival. These results
require validation in subsequent investigations.
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